127232-42-2

Basic information

• Product Name: 5-(BROMOMETHYL)OXAZOLE
• Synonyms: 5-(BROMOMETHYL)OXAZOLE;OXAZOLE, 5-(BROMOMETHYL)-;5-(Bromomethyl)-1,3-oxazole;5-(Bromomethyl)oxazole ,95%
• CAS NO: 127232-42-2
• Molecular Formula: C₄H₄BrNO
• Molecular Weight: 161.98
• Mol File: 127232-42-2.mol

Chemical Properties

• Boiling Point: 192.621 °C at 760 mmHg
• Flash Point: 70.295 °C
• Appearance: /
• Density: 1.706 g/cm³
• Vapor Pressure: 0.675mmHg at 25°C
• Refractive Index: 1.529
• CAS DataBase Reference: 5-(BROMOMETHYL)OXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(BROMOMETHYL)OXAZOLE(127232-42-2)
• EPA Substance Registry System: 5-(BROMOMETHYL)OXAZOLE(127232-42-2)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 127232-42-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-(Bromomethyl)oxazole is used as a building block for the preparation of medicinal compounds and agrochemicals, leveraging its reactivity to facilitate the formation of complex molecular structures.
Used in Pharmaceutical Drug Synthesis:
As a precursor, 5-(Bromomethyl)oxazole is utilized in the synthesis of pharmaceutical drugs, contributing to the development of new medications with potential therapeutic benefits.
Used in the Development of New Materials:
5-(Bromomethyl)oxazole is also employed in the development of new materials, indicating its potential applications across various industries beyond pharmaceuticals and agrochemicals.
Used in Chemical Reactions:
5-(Bromomethyl)oxazole is used as a reagent in various chemical reactions, particularly for the formation of carbon-carbon and carbon-heteroatom bonds, which are crucial in creating new chemical entities with specific properties and functions.

InChI:InChI=1/C4H4BrNO/c5-1-4-2-6-3-7-4/h2-3H,1H2

Upstream product

• 127232-41-1 1,3-oxazol-5-ylmethanol 

Relevant articles and documents

Compounds and methods of use

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

SUBSTITUTED OXOPYRIDINE DERIVATIVES

The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

SUBSTITUTED OXOPYRIDINE DERIVATIVES

The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

SUBSTITUTED OXOPYRIDINE DERIVATIVES

The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

As tyrosine kinase inhibitors substituted indolinone derivatives

The invention belongs to the technical field of a medicine, and particularly relates to a substituted indole ketone derivative as a tyrosine kinase inhibitor shown in a general formula (I), a pharmaceutically acceptable salt, a deuterated article or a stereoisomer thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, Ra, Rb, Rc, Rd, n, n1, n2, n3, n4, a ring A and a ring B are defined in the specification. The invention also relates to a preparation method of the compound, a drug preparation containing the compound, and application of the compound in preparation of a drug for preventing or treating a fibrosis disease and treating an excessive hyperplasia disease.

SUBSTITUTED OXOPYRIDINE DERIVATIVES

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS

The present invention relates to a compound of formula (1-1 ) in free form or in pharmaceutically acceptable salt form in which the substituents are as defined in the specification; to its preparation, to its use as a medicament and to medicaments comprising it. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Highly enantioselective mukaiyama aldol reactions catalyzed by a chiral oxazaborolidinium ion: Total synthesis of (-)-inthomycin C

A cationic oxazaborolidinium-catalyzed asymmetric Mukaiyama aldol reaction of (1-methoxy-2-methyl-propenyloxy)-trimethylsilane with various aldehydes including α,β-disubstituted acroleins has been developed in high yields and enantioselectivities. The synthetic utility of this methodology was demonstrated in the first short synthesis of naturally occurring inthomycin C in high enantiopurity.

The syntheses of rac-inthomycin A, (+)-inthomycin B and (+)-inthomycin C using a unified synthetic approach

The Stille coupling between a common oxazole vinyl iodide and stereodefined stannyl-diene units is described as the cornerstone of a unified synthetic route to the inthomycin family of bioactive Streptomyces metabolites. This procedure has been utilised to prepare (+)-inthomycin B and (+)-inthomycin C for the first time; in these examples the stereogenic centre was introduced using the Kiyooka ketene acetal/amino acid-derived oxazaborolidinone variant of the Mukaiyama aldol reaction. In addition, a convenient preparation of rac-inthomycin A is described based on the same strategy.

A general route to the Streptomyces-derived inthomycin family: The first synthesis of (+)-inthomycin B

A concise, convergent and stereocontrolled synthesis of (+)-inthomycin B, based on the Stille coupling of a stannyl-diene with an oxazole vinyl iodide unit, is described. The asymmetric centre was introduced using the Kiyooka ketene acetal/amino acid-derived oxazaborolidinone procedure.